Delivery Order SPE2DB20D2014-SPE2DB24FA51U
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Multaq 400 mg tablets. The $13,025.00 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to supply a comprehensive range of pharmaceutical products...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of Multaq 400 mg tablets. The single-award contract has a ceiling value of $1,529.88 and runs through March 2025. It is a firm fixed-price delivery order contract, with no set-aside designation indicated. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under DLA's Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Multaq 400 mg tablets. The $31,110.42 firm-fixed-price delivery order has a completion date of February 15, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
- This federal contract award, valued at $19,119.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Multaq 400 mg tablets and is a firm-fixed-price delivery order with no set-aside requirements. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., maintains a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award is for a delivery order valued at $19,542.63, awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the pharmaceutical product Multaq 400 mg tablet, with an ultimate completion date of December 10, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,019.92 firm fixed-price delivery order is for the supply of 4568161278 Multaq 400 mg tablets. The contract has an ultimate completion date of May 7, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,785.46, is a Delivery Order for Multaq 400 mg Tablets. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,367.37 fixed-price delivery order is for the supply of Multaq 400 mg tablets, with a completion date of November 13, 2024. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Multaq 400 mg tablets. The $14,321.03 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), which is a defense agency. The contract has an ultimate completion date of October 30, 2024. There is no set-aside designation noted for this award. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB24FA51UDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,044.29, is for the delivery of Multaq 400 mg tablets. The award was made as a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 12/6/23 |